We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Gonadorelinis a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Gonadorelin studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality studies published 1988–2024 with a typical study size of 76 participants.
Based on 11 studies · 2,014 total participants
Confidence
LowBy outcome
Gonadorelin has an evidence score of 4/10 — emerging evidence based on 11 indexed studies. A synthetic copy of gonadotropin-releasing hormone (GnRH), the hypothalamic decapeptide that drives the pituitary to release LH and FSH. Honest appraisal: it has genuine, trial-backed roles as a diagnostic agent (the GnRH/gonadorelin stimulation test) and — delivered in pulses by an infusion pump — for inducing ovulation in hypothalamic amenorrhea and spermatogenesis in men with congenital hypogonadotropic hypogonadism. Its now-trendy use in men's TRT clinics (compounded, to 'maintain testosterone/fertility' alongside testosterone, often replacing hCG) is largely off-label and has NOT been validated in controlled trials for that purpose. Representative study: PMID 12213860.
The commonly studied dose of Gonadorelin is Prescription-only and delivery-dependent. Diagnostically, a single bolus (e.g. 100 µg) is given. For fertility, pulsatile delivery via an infusion pump is required — historic regimens used ~75 ng/kg/pulse (women, often IV) or 5-25 ng/kg/pulse titrated (men, sc), every ~90 minutes. No validated dietary-supplement dose exists; intermittent subcutaneous bolus dosing as used in some TRT clinics is off-label and not validated.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
PT-141
Mostly mechanism / observationalA melanocortin-receptor (MC4R) agonist peptide for low sexual desire. Important honest framing: unlike most 'research peptides', bremelanotide is an FDA-APPROVED prescription drug — Vyleesi, approved 2019 — for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, self-injected subcutaneously on-demand. It has real phase-3 RCTs (the RECONNECT program). The catch: the approved-trial benefit was statistically significant but small (a fraction of a point on desire scales), nausea is very common, and it transiently raises blood pressure. Grey-market 'PT-141' vials sold online are NOT the approved drug and are unregulated.
Notable regimens that report including Gonadorelin — documented, not endorsed.
Last reviewed June 2026 · evidence from 11 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Gonadorelin (synthetic GnRH)
A synthetic copy of gonadotropin-releasing hormone (GnRH), the hypothalamic decapeptide that drives the pituitary to release LH and FSH. Honest appraisal: it has genuine, trial-backed roles as a diagnostic agent (the GnRH/gonadorelin stimulation test) and — delivered in pulses by an infusion pump — for inducing ovulation in hypothalamic amenorrhea and spermatogenesis in men with congenital hypogonadotropic hypogonadism. Its now-trendy use in men's TRT clinics (compounded, to 'maintain testosterone/fertility' alongside testosterone, often replacing hCG) is largely off-label and has NOT been validated in controlled trials for that purpose.
Pulsatile pump-delivered GnRH has solid observational evidence for ovulation induction and spermatogenesis plus a validated diagnostic test, but there are no RCTs or meta-analyses, and the trendy intermittent-injection TRT-clinic use is unvalidated.
Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH), the decapeptide normally released in pulses by the hypothalamus to stimulate the anterior pituitary to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
It is a prescription drug (historically marketed as Factrel and, for pump use, Lutrelef/Lutrepulse), not a dietary supplement.
Because native GnRH has a very short circulating half-life (minutes), the way it is delivered matters enormously: a single bolus is used diagnostically (the GnRH/gonadorelin stimulation test, where the LH/FSH response distinguishes central precocious puberty, hypogonadotropic hypogonadism, and pubertal staging), whereas treatment of infertility requires pulsatile delivery via a programmable infusion pump that mimics the natural ~90-minute hypothalamic rhythm.
The strongest human evidence is for these two uses.
In women with hypothalamic amenorrhea or congenital GnRH deficiency, pulsatile GnRH reliably induces ovulation and pregnancy, with high cumulative conception rates and — importantly — a lower risk of multiple gestation and ovarian hyperstimulation than exogenous gonadotropins.
In men with idiopathic/congenital hypogonadotropic hypogonadism, pulsatile GnRH induces virilization and spermatogenesis, with outcomes predicted by prior pubertal development, baseline inhibin B, and absence of cryptorchidism.
Crucially, these are the validated indications — and they depend on intact pituitary gonadotropes, pump-delivered pulsatility, and a specific patient population.
The popular men's-TRT-clinic practice of injecting gonadorelin subcutaneously a few times a week (often instead of hCG, to 'keep the testes working' while on exogenous testosterone) is a different proposition: its short half-life makes intermittent subcutaneous bolus dosing pharmacologically very different from pump-delivered pulsatility, and there are essentially no controlled trials demonstrating that this regimen preserves testicular function, intratesticular testosterone, or fertility in men on TRT.
That use is off-label and uncontrolled. So the honest picture is two-tiered: real, evidence-backed diagnostic and pulsatile-fertility uses on one side, and a trendy but largely unvalidated TRT-clinic use on the other.
Gonadorelin is identical to native GnRH; it binds GnRH receptors on anterior-pituitary gonadotrophs, the upstream master switch of the reproductive (hypothalamic-pituitary-gonadal) axis.
Receptor activation triggers secretion of LH and FSH. The response depends on delivery: a single bolus gives an acute diagnostic LH/FSH rise, while sustained pump-delivered pulses (every ~90 min) are needed to drive ongoing gonadal stimulation. Continuous (non-pulsatile) exposure paradoxically desensitizes the pituitary.
Pulsatile LH/FSH stimulates the ovary to grow follicles and ovulate, and the testis to produce testosterone (Leydig cells) and sperm (Sertoli-cell-supported spermatogenesis) — provided the pituitary and gonads are intact.
How Gonadorelin works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Prescription-only and delivery-dependent. Diagnostically, a single bolus (e.g. 100 µg) is given. For fertility, pulsatile delivery via an infusion pump is required — historic regimens used ~75 ng/kg/pulse (women, often IV) or 5-25 ng/kg/pulse titrated (men, sc), every ~90 minutes. No validated dietary-supplement dose exists; intermittent subcutaneous bolus dosing as used in some TRT clinics is off-label and not validated.
Can be taken without food
| Form | Type |
|---|---|
| 🍵Gonadorelin acetate (prescription; pulsatile infusion pump for fertility, single bolus for diagnostics) | Recommended |
A prescription drug, not a dietary supplement. For fertility it requires a programmable pump to deliver the pulses; intermittent self-injection (as marketed by some TRT clinics) is off-label and pharmacologically different from the validated pulsatile regimen.
Minimum: 2 weeks
Optimal: 24 weeks
Cycling: Not required
Note: Fertility use is continuous pulsatile pump delivery (every ~90 minutes), not a single daily dose. Diagnostic use is a one-time bolus. These are clinical protocols, not supplement timing.
Dose-response data unavailable. The current published research for Gonadorelin does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
A single dose produces a measurable LH/FSH rise used to evaluate central precocious puberty, pubertal status, and hypogonadotropic hypogonadism — a well-established diagnostic test.
Pump-delivered pulsatile GnRH reliably induces ovulation and pregnancy in hypothalamic amenorrhea, with less multiple gestation and hyperstimulation than gonadotropins.
Pulsatile GnRH induces virilization and sperm production in men with congenital/idiopathic hypogonadotropic hypogonadism; outcome depends on prior puberty, inhibin B, and cryptorchidism history.
Intermittent subcutaneous gonadorelin used in men's-TRT clinics (often replacing hCG) is off-label; its short half-life makes non-pump bolus dosing pharmacologically different from validated pulsatile therapy, and controlled evidence for this use is essentially absent.
This off-label, compounded use is not validated by controlled trials; intermittent sc dosing differs from the pump-delivered pulsatile therapy that the evidence supports. Discuss alternatives (e.g. hCG, sperm banking) with a reproductive endocrinologist.
The gonadorelin/GnRH stimulation test is an established pediatric diagnostic tool, performed under specialist supervision — not a treatment.
Avoid — stimulating the gonadal axis could be harmful; specialist input required.
Fertility use is clinician-supervised and stopped at conception; not for self-administration.
Exogenous androgens suppress the hypothalamic-pituitary axis; the rationale for adding gonadorelin in TRT clinics is to offset this, but whether intermittent sc gonadorelin actually preserves the axis or fertility on TRT is not established by controlled trials.
These drugs occupy or down-regulate the same receptor; co-use is contradictory and would blunt or block the gonadorelin response.
Tip: Rotate sites; with pump therapy, manage the indwelling catheter site carefully
Tip: Lower than with gonadotropins, but monitor follicles by ultrasound during ovulation induction
Tip: Usually transient
Tip: Sterile technique and site monitoring; subcutaneous route reduces this risk
Timing is flexible for Gonadorelin — consistent daily use matters more than the time of day. For fertility, dosing is continuous pulsatile delivery by pump (every ~90 min) to mimic the natural hypothalamic rhythm — not a once-daily schedule.
Gonadorelin should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are injection-site reaction (pain, redness, swelling), multiple pregnancy / ovarian enlargement (fertility use), headache, flushing, nausea, abdominal discomfort. Use caution if any of these apply to you: Pregnancy (fertility treatment is supervised; not a self-administered agent); Hormone-sensitive tumors / conditions worsened by gonadal stimulation; Use without medical supervision.
Sermorelin
Mostly mechanism / observationalAn injectable analogue of growth-hormone-releasing hormone (the first 29 amino acids of GHRH) that stimulates the pituitary to release growth hormone. Honest appraisal: this WAS an FDA-approved prescription drug (Geref) with real human trials — for diagnosing GH deficiency and treating GH-deficient children — but it was discontinued commercially. Its current marketing as a compounded 'anti-aging' peptide is off-label and is NOT what those trials validated.
Several drugs alter pituitary gonadotropin responsiveness and can confound the GnRH stimulation test or the therapeutic response.